/****** Font Awesome ******/ /****** Collapsing Nested Menu Items | Code by Elegant Themes ******/

FLUCOP (IMI)

 

 BACK | NEXT 

Despite the development and licensure of influenza vaccines along with clinical evidence of their ability to protect against influenza, the potential correlates of protection induced by these vaccines are still not fully elucidated. The availability of a tool-box of standardised, validated serological assays for human influenza vaccines, agreed and used by key parties in the private and in the public sector will have tremendous impact on the R&D process globally, and will pave the way for future investigation and definition of correlates of protection for these vaccines. Artemis forms part of a consortium that will evaluate the use of cell-mediated immunity and neuraminidase assays as tools for assessing influenza vaccine performance. Artemis One Health is involved in the development of novel analytical approaches to population-based evaluation of influenza vaccine effectiveness, in particular in the elderly.